The U.S. Food and Drug Administration approved BioXcel Therapeutics Inc.’s IGALMI (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
https://www.pharmalive.com/wp-content/uploads/2022/04/BioXcel-Therapeutics-logo.png122414GlobeNewswirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngGlobeNewswire2022-04-06 11:05:032022-04-06 11:10:41BioXcel Therapeutics Announces FDA Approval of IGALMI Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults